Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mangoceuticals (MGRX) Change in Accured Expenses (2023 - 2025)

Mangoceuticals' Change in Accured Expenses history spans 3 years, with the latest figure at -$276656.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 54.11% year-over-year to -$276656.0; the TTM value through Sep 2025 reached $151838.0, up 468.55%, while the annual FY2024 figure was -$27000.0, 125.21% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was -$276656.0 at Mangoceuticals, down from $89816.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $875180.0 in Q1 2024 and bottomed at -$602885.0 in Q3 2024.
  • The 3-year median for Change in Accured Expenses is -$2000.0 (2024), against an average of $21266.2.
  • The largest YoY upside for Change in Accured Expenses was 6480.72% in 2024 against a maximum downside of 1365.23% in 2024.
  • A 3-year view of Change in Accured Expenses shows it stood at $51706.0 in 2023, then plummeted by 103.87% to -$2000.0 in 2024, then tumbled by 13732.8% to -$276656.0 in 2025.
  • Per Business Quant, the three most recent readings for MGRX's Change in Accured Expenses are -$276656.0 (Q3 2025), $89816.0 (Q2 2025), and $340678.0 (Q1 2025).